Update on triple-negative breast cancer: prognosis and management strategies

被引：114

作者：

Brouckaert, Olivier ^{[1
]}

Wildiers, Hans ^{[1
]}

Floris, Giuseppe ^{[1
]}

Neven, Patrick ^{[1
]}

机构：

[1] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium

来源：

INTERNATIONAL JOURNAL OF WOMENS HEALTH | 2012年 / 4卷

关键词：

breast cancer; triple negative; review;

D O I：

10.2147/IJWH.S18541

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%-20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particular clinical presentation and outcome. All these features will be discussed in this review. The risk of developing TNBC varies with age, race, genetics, breastfeeding patterns, and parity. Some TNBC are very chemo-sensitive and the majority of patients confronted with and treated for TNBC will never relapse. Some (histological) subgroups of TNBC may have good prognosis even in the absence of chemotherapy. Distinct molecular subgroups within TNBC have been defined now as well. In case metastatic relapse occurs, this is usually within 5 years following surgery, and survival following metastatic relapse is shorter compared to other breast cancer subtypes; treatment options are few and responses lack durability. Novel drug targets and new biomarkers are needed to improve breast cancer care for patients presenting with TNBC. Further molecular/biological unraveling of TNBC is needed.

引用

页码：511 / 520

页数：10

共 114 条

[1] Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study [J].

Alba, E. ;

Chacon, J. I. ;

Lluch, A. ;

Garcia-Estevez, L. ;

Anton, A. ;

Cirauqui, B. ;

Lopez Garcia-Asenjo, J. A. ;

Carrasco, E. M. ;

Rodriguez, C. ;

Escudero, M. J. ;

Sanchez, A. ;

Ribelles, N. ;

Romero, C. ;

Alvarez, J. ;

Albanell, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[2] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[3] Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool? [J].

Albergaria, Andre ;

Ricardo, Sara ;

Milanezi, Fernanda ;

Carneiro, Vtor ;

Amendoeira, Isabel ;

Vieira, Daniella ;

Cameselle-Teijeiro, Jorge ;

Schmitt, Fernando .

BMC CANCER, 2011, 11

[4] Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer [J].

Aleskandarany, Mohammed A. ;

Green, Andrew R. ;

Benhasouna, Ahmed A. ;

Barros, Fabricio F. ;

Neal, Keith ;

Reis-Filho, Jorge S. ;

Ellis, Ian O. ;

Rakha, Emad A. .

BREAST CANCER RESEARCH, 2012, 14 (01)

[5] Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer [J].

Allred, D. Craig .

MODERN PATHOLOGY, 2010, 23 :S52-S59

[6] Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].

Amir, Eitan ;

Miller, Naomi ;

Geddie, William ;

Freedman, Orit ;

Kassam, Farrah ;

Simmons, Christine ;

Oldfield, Maria ;

Dranitsaris, George ;

Tomlinson, George ;

Laupacis, Andreas ;

Tannock, Ian F. ;

Clemons, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592

[7] Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction [J].

Antoniou, Antonis C. ;

Beesley, Jonathan ;

McGuffog, Lesley ;

Sinilnikova, Olga M. ;

Healey, Sue ;

Neuhausen, Susan L. ;

Ding, Yuan Chun ;

Rebbeck, Timothy R. ;

Weitzel, Jeffrey N. ;

Lynch, Henry T. ;

Isaacs, Claudine ;

Ganz, Patricia A. ;

Tomlinson, Gail ;

Olopade, Olufunmilayo I. ;

Couch, Fergus J. ;

Wang, Xianshu ;

Lindor, Noralane M. ;

Pankratz, Vernon S. ;

Radice, Paolo ;

Manoukian, Siranoush ;

Peissel, Bernard ;

Zaffaroni, Daniela ;

Barile, Monica ;

Viel, Alessandra ;

Allavena, Anna ;

Dall'Olio, Valentina ;

Peterlongo, Paolo ;

Szabo, Csilla I. ;

Zikan, Michal ;

Claes, Kathleen ;

Poppe, Bruce ;

Foretova, Lenka ;

Mai, Phuong L. ;

Greene, Mark H. ;

Rennert, Gad ;

Lejbkowicz, Flavio ;

Glendon, Gord ;

Ozcelik, Hilmi ;

Andrulis, Irene L. ;

Thomassen, Mads ;

Gerdes, Anne-Marie ;

Sunde, Lone ;

Cruger, Dorthe ;

Jensen, Uffe Birk ;

Caligo, Maria ;

Friedman, Eitan ;

Kaufman, Bella ;

Laitman, Yael ;

Milgrom, Roni ;

Dubrovsky, Maya .

CANCER RESEARCH, 2010, 70 (23) :9742-9754

[8] The pathology of inherited breast cancer [J].

Armes, JE ;

Venter, DJ .

PATHOLOGY, 2002, 34 (04) :309-314

[9] KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome [J].

Azoulay, S ;

Laé, M ;

Fréneaux, P ;

Merle, S ;

Al Ghuzlan, A ;

Chnecker, C ;

Rosty, C ;

Klijanienko, J ;

Sigal-Zafrani, B ;

Salmon, R ;

Fourquet, A ;

Sastre-Garau, X ;

Vincent-Salomon, A .

MODERN PATHOLOGY, 2005, 18 (12) :1623-1631

[10]

Baldwin RL, 2000, CANCER RES, V60, P5329

← 1 2 3 4 5 6 7 8 9 10 →